Sanctuary Advisors LLC Buys New Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Sanctuary Advisors LLC purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,437 shares of the company’s stock, valued at approximately $507,000.

Other hedge funds also recently bought and sold shares of the company. Janus Henderson Group PLC increased its position in Vaxcyte by 23.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after purchasing an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. boosted its stake in shares of Vaxcyte by 5.9% during the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock worth $992,914,000 after purchasing an additional 485,436 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Vaxcyte by 47.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock worth $148,075,000 after buying an additional 419,600 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Vaxcyte in the third quarter valued at approximately $41,114,000. Finally, Maverick Capital Ltd. lifted its stake in shares of Vaxcyte by 93.7% during the second quarter. Maverick Capital Ltd. now owns 687,908 shares of the company’s stock valued at $51,944,000 after buying an additional 332,777 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Buying and Selling

In related news, SVP Mikhail Eydelman sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $109.27, for a total transaction of $546,350.00. Following the transaction, the senior vice president now directly owns 28,623 shares of the company’s stock, valued at approximately $3,127,635.21. The trade was a 14.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew Guggenhime sold 42,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares of the company’s stock, valued at approximately $10,429,294.37. This represents a 31.73 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 117,830 shares of company stock valued at $12,383,030. Company insiders own 3.10% of the company’s stock.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX opened at $85.91 on Thursday. The stock has a 50-day simple moving average of $96.95 and a 200-day simple moving average of $92.58. The stock has a market capitalization of $10.71 billion, a P/E ratio of -18.68 and a beta of 0.94. Vaxcyte, Inc. has a 1 year low of $53.83 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the previous year, the company earned ($0.91) EPS. Analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Mizuho boosted their price target on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. BTIG Research increased their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. The Goldman Sachs Group assumed coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Leerink Partners increased their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte has a consensus rating of “Buy” and an average target price of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.